ReviewVaccine2011
TLR-based immune adjuvants.
Review in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
241 citing papers in PubMed, 497 citations in OpenAlex.
- CpG-ODN/Coa-ASC16 nanostructured adjuvant platform as a safe and effective alternative in Bothrops diporus antivenom production.Archives of toxicology · 2026Article
- Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant.mSphere · 2026Article
- Timing of florfenicol administration determines the protective efficacy of an Actinobacillus pleuropneumoniae live attenuated vaccine in pigs.BMC veterinary research · 2026Article
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Bacterial ghosts (BGs): A promising approach as candidate vaccine.World journal of microbiology & biotechnology · 2026Review
- Review
- Article
- In Vivo Evaluation of PamJournal of peptide science : an official publication of the European Peptide Society · 2025Article
- Engineered bacteria: Strategies and applications in cancer immunotherapy.Fundamental research · 2025Review
- Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4.NPJ vaccines · 2025Article
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.NPJ vaccines · 2025Article
- Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.International journal of molecular sciences · 2025Article
- AI discovery of TLR agonist-driven phenotypes reveals unique features of peripheral cells from healthy donors and ART-suppressed people living with HIV.Frontiers in immunology · 2025Article
- Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy.Journal of immunology research · 2025Article
- The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications.Frontiers in immunology · 2025Review
- Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity.Frontiers in immunology · 2025Review
- Single-Cell Data and Weighted Correlation Network Analysis Revealed the Regulatory Mechanisms of Macrophages in Carotid Plaques.Journal of immunology research · 2025Article
- Immune Responses Elicited by Outer Membrane Vesicles of Gram-Negative Bacteria: Important Players in Vaccine Development.Life (Basel, Switzerland) · 2024Review
- Molecular mechanisms ofInfection and immunity · 2024Article
181 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.